A mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. iECURE’s approach focuses on the in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.
Location: United States, Pennsylvania, Philadelphia
Member count: 11-50
Total raised: $115M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 02.12.2022 | Series A | $65M | - | finsmes.co... |
| 09.09.2021 | - | $50M | - | fiercebiot... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 30.11.2022 | iECURE Rai... | iECURE, a Philadelphia, PA-bas... | USA | - | finsmes.co... |
| 30.11.2022 | iECURE Rai... | PHILADELPHIA, PA, iECURE, a ... | - | - | vcnewsdail... |
| 09.09.2021 | iECURE eme... | iECURE is emerging from stealt... | Biotech | - | fiercebiot... |
| - | iECURE | “Home | iECURE” | - | - | fastfounde... |